Episode Details
Back to Episodes296. Guidelines: 2021 ESC Cardiovascular Prevention – Question #24 with Dr. Jaideep Patel
Description
The following question refers to Section 6.3 of the 2021 ESC CV Prevention Guidelines. The question is asked by Dr. Christian Faaborg-Andersen, answered first by UCSD cardiology fellow Dr. Harpreet Bhatia, and then by expert faculty Dr. Jaideep Patel.
Dr. Patel recently graduated from Virginia Commonwealth University cardiology fellowship and is now a preventive cardiologist at the Johns Hopkins Hospital.
The CardioNerds Decipher The Guidelines Series for the 2021 ESC CV Prevention Guidelines represents a collaboration with the ACC Prevention of CVD Section, the National Lipid Association, and Preventive Cardiovascular Nurses Association.
|
A 65-year-old man with a history of ischemic stroke 6 months ago presents to cardiology clinic to establish care. An event monitor was negative for atrial fibrillation and TTE with agitated saline study was negative for a patent foramen ovale. Therefore, his ischemic stroke was presumed to be non-cardioembolic in origin. He is currently taking lisinopril 5 mg daily for hypertension (BP in clinic is 115/70) and atorvastatin 40 mg daily. He has no history of significant gastrointestinal or other bleeding. What do you recommend next? |
|
|
A |
Start apixaban 5 mg BID |
|
B |
Increase lisinopril to 10 mg daily |
|
C |
Start aspirin 81 mg daily |
|
D |
Start aspirin 81 mg daily and clopidogrel 75 mg daily |
|
E |
Start aspirin 81 mg daily and ticagrelor 90 mg BID |
|
Explanation |
The correct answer is C – start aspirin 81mg daily. For the secondary pre Listen NowLove PodBriefly?If you like Podbriefly.com, please consider donating to support the ongoing development. Support Us |